Abstract:Mitochondrial GCN5L1 regulates proliferation and tumorigenesis in hepatocellular carcinoma (HCC) via glutamine metabolism. Deletion of general control of amino acid synthesis 5 like 1 (GCN5L1) enhances both glutaminase 1 (GLS1) and glutaminase 2 (GLS2) activities by altering acetylation and oligomerisation. Compound 968 inhibits GLS2 to suppress diethylnitrosamine (DEN)‐ and carbon tetrachloride (CCl4)‐induced HCC development. Our study suggests that targeting glutaminase or mTORC1 activity could be a potential therapeutic treatment for HCC expressing lower levels of GCN5L1. Background Glutaminolysis is a critical metabolic process that promotes cancer cell proliferation, including hepatocellular carcinoma (HCC). Delineating the molecular control of glutaminolysis could identify novel targets to ameliorate this oncogenic metabolic pathway. Here, we evaluated the role of general control of amino acid synthesis 5 like 1 (GCN5L1), a regulator of mitochondrial protein acetylation, in modulating the acetylation and activity of glutaminase to regulate HCC development. Methods Cell proliferation was determined by MTT, 2D and soft agar clone formation assays and orthotopic tumour assays in nude mice. GLS1/2 acetylation and activities were measured in cells and tumours to analyse the correlation with GCN5L1 expression and mTORC1 activation. Results Hepatic GCN5L1 ablation in mice markedly increased diethylnitrosamine (DEN)‐induced HCC, and conversely, the transduction of mitochondrial‐restricted GCN5L1 protected wild‐type mice against HCC progression in response to DEN and carbon tetrachloride (CCl4) exposure. GCN5L1–depleted HepG2 hepatocytes enhanced tumour growth in athymic nude mice. Mechanistically, GCN5L1 depletion promoted cell proliferation through mTORC1 activation. Interestingly, liver–enriched glutaminase 2 (GLS2) appears to play a greater role than ubiquitous and canonical tumour–enriched glutaminase 1 (GLS1) in promoting murine HCC. Concurrently, GCN5L1 promotes acetylation and inactivation of both isoforms and increases enzyme oligomerisation. In human HCC tumours compared to adjacent tissue, there were variable levels of mTORC1 activation, GCN5L1 levels and glutaminase activity. Interestingly, the levels of GCN5L1 inversely correlated with mTORC1 activity and glutaminase activity in these tumours. Conclusions Our study identified that glutaminase activity, rather than GLS1 or GLS2 expression, is the key factor in HCC development that activates mTORC1 and promotes HCC. In the Kaplan–Meier analysis of liver cancer, we found that HCC patients with high GCN5L1 expression survived longer than those with low GCN5L1 expression. Collectively, GCN5L1 functions as a tumour regulator by modulating glutaminase acetylation and activity in the development of HCC.

Lysine Acetyltransferase GCN5 Potentiates the Growth of Non-small Cell Lung Cancer via Promotion of E2F1, Cyclin D1, and Cyclin E1 Expression

The Prognostic Role of Eg5 Expression in Laryngeal Squamous Cell Carcinoma.

EXOSC5 Promotes Proliferation of Gastric Cancer Through Regulating AKT/STAT3 Signaling Pathways.

The Histone Acetyltransferase GCN5 Expression is Elevated and Regulated by C-Myc and E2F1 Transcription Factors in Human Colon Cancer.

C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation

LCAT1 is an Oncogenic LncRNA by Stabilizing the IGF2BP2-CDC6 Axis

Histone acetyl transferase GCN5 promotes human hepatocellular carcinoma progression by enhancing AIB1 expression

Transcriptional Activation of MYC-Induced Genes by GCN5 Promotes B-cell Lymphomagenesis

GCN5 Potentiates Glioma Proliferation and Invasion via STAT3 and AKT Signaling Pathways

E2F1 Induces LSINCT5 Transcriptional Activity and Promotes Gastric Cancer Progression by Affecting the Epithelial-Mesenchymal Transition

Eg5 As a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma

Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma

GRK5 functions as an oncogenic factor in non-small-cell lung cancer

Lysine methyltransferase 5C increases the proliferation and metastatic abilities of clear cell renal cell carcinoma via aerobic glycolysis

CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt/β-catenin signalling pathway

GPC5 suppresses lung cancer progression and metastasis via intracellular CTDSP1/AhR/ARNT signaling axis and extracellular exosome secretion

EVI5 is an Oncogene That Regulates the Proliferation and Metastasis of NSCLC Cells

E2F1 and MYC activated SNHG15 promotes gastric cancer progression via interacting with miR-24-3p to regulate cell cycle and ferroptosis

Long Noncoding RNA CTD-2245E15.3 Promotes Anabolic Enzymes ACC1 and PC to Support Non–Small Cell Lung Cancer Growth

Molecular Mechanism of Cyclin E1 in Lung Adenocarcinoma and Their Cellular Response

A Critical Role for the Long Non‐coding RNA GAS5 in Proliferation and Apoptosis in Non‐small‐cell Lung Cancer